Brain Amylin Signaling, Feeding, and Reward.
This review paper examines the role of amylin — a pancreatic hormone — in regulating food intake, body weight, and reward processing through its actions in the brain. The authors outline how early research focused on hindbrain regions as the primary sites where amylin suppresses feeding, but highlight more recent evidence pointing to mesolimbic brain structures (associated with reward and motivation) as additional key targets. The review discusses findings suggesting that amylin signaling in these reward-related areas influences not only consumption of palatable foods but also responses to drugs of abuse, raising important considerations for the development of amylin-based obesity therapies. The paper is contextualized within the broader landscape of obesity treatment, acknowledging the success of GLP-1 receptor agonists while arguing that amylin represents a complementary pharmacological avenue. As a narrative review, the paper synthesizes existing literature rather than presenting new experimental data, meaning its conclusions are only as strong as the individual studies it draws upon. It does not provide direct clinical trial evidence, and the breadth of findings discussed spans animal models and limited human data, which constrains the translational certainty of its conclusions.
Why this grade: This is a narrative review synthesizing preclinical and clinical literature; it generates no original experimental data, so evidence grading reflects the review design rather than direct human trial evidence.
Obesity is a disease that is both costly and prevalent, and although the development and use of glucagon-like peptide-1 receptor agonists has dramatically altered the landscape of obesity treatment, there remains a need to identify alternate approaches to reduce body weight. Amylin, a pancreatic hormone, has been viewed as a favorable candidate for novel obesity pharmacotherapies due to its ability to suppress feeding and body weight through its actions in the brain. Although research initially focused on hindbrain sites of action for amylin, more recent work has identified other central nuclei at which amylin influences food intake and food reward. This review discusses the growing body of literature suggesting that amylin signaling in mesolimbic structures of the brain influences food intake and reward processing. These effects are observed for palatable food as well as other reinforcing stimuli such as drugs of abuse. This is an important area of research as the broad effects of amylin-based pharmacotherapies should be considered when developing new obesity medications.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.